Partners
“Functional recovery once deemed impossible may now be in reach.”
Marco Baptista, Ph.D., Chief Scientific Officer
Christopher & Dana Reeve Foundation
“I have been following this closely for over 20 years, nothing like this has been brought to the clinical setting.”
Kevin Schultes, Chairman of the Executive Board
German Spinal Injuries Association (FGQ)
To register for email alerts,
submit a form below
The ONWARD® Medical ARCEX® System is FDA cleared for use in the United States and CE marked in accordance with EU Medical Device Regulation 2017/745. ONWARD ARCIM® and ARCBCI™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
Indication for Use (US): The ARCEX® System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old who present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).
Indication for Use (EU): The ARCEX® System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic and with take-home exercises in the home to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).